Jon Faiz Kayyem
CIK 1366268 · SVP, Research & Development · last filed 2026-09-23
Jon Faiz Kayyem is a SVP, Research & Development who has filed 104 SEC Form 4 insider transactions across 4 companies since 2010. The most recent filing shows the insider bought $500.0K of INBX on Sep 23, 2026. Across all open-market trades the lifetime net is +$2.3M, making them a net buyer over the disclosed history. Current disclosed insider exposure totals $40.0M across reported positions. 21 SEC filings were submitted jointly with Efficacy Biotech Master Fund Ltd.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GNMK price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
CARLSBAD, CA 92008
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| INBX | Director | 434,360 | $91.74 | $39.85M | $3.02M | 22 | 2026-09-23 |
| BDSX | Director | 17,877 | $10.34 | $184.8K | $200.0K | 13 | 2026-01-06 |
| Inhibrx, Inc. (INBXV) Delisted | Director | 0 | — | — | $0 | 1 | 2024-05-30 |
| GenMark Diagnostics, Inc. (GNMK) Delisted | SVP, Research & Development | 286,306 | $24.04 | $6.88M | -$924.2K | 62 | 2018-02-06 |
Recent Filings
104 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-09-23 | INBX | Buy (P) | +5,000 | $500.0K | EDGAR |
| 2026-09-18 | INBX | Grant (A) | — | $0 | EDGAR |
| 2026-09-17 | INBX | Buy (P) | +5,000 | $500.0K | EDGAR |
| 2026-09-08 | INBX | Buy (P) | +5,000 | $567.6K | EDGAR |
| 2026-06-04 | INBX | Grant (A) | — | $0 | EDGAR |
| 2026-01-06 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2025-05-29 | INBX | Grant (A) | — | $0 | EDGAR |
| 2025-05-22 | BDSX | Grant (A) | — | $0 | EDGAR |
| 2025-03-28 | INBX | Gift (G) | −90,000 | $0 | EDGAR |
| 2024-12-17 | INBX | Gift (G) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.